New pediatric vitiligo registry data presented at the Society for Pediatric Dermatology 2026 Annual Meeting reveal that while long-term clearance is achievable for most children, optimal responses can take 3 or more years. According to Nanette Silverberg, chief of pediatric dermatology for Mount Sinai Health Systems, findings from 351 evaluated children indicate that treatment outcomes vary based on disease subtype, location, and other variables.
Poliosis Identifies High-Risk Vitiligo Patients
The retrospective cohort registry highlights poliosis as a risk factor for never repigmenting. According to Silverberg, patients presenting with poliosis experience a rate of poor response to common vitiligo therapies that is several times higher than in patients without the condition.
Segmental Versus Nonsegmental Head and Neck Responses
A specific head and neck substudy tracking 202 pediatric patients aged 1 to 18 years compared outcomes between those with segmental versus nonsegmental vitiligo. According to the registry data, the 163 patients with nonsegmental vitiligo achieved a mean body surface area (BSA) reduction of nearly 90% at 12 months. In contrast, the 39 patients with segmental disease recorded a mean BSA reduction of 55.0% over the same timeframe.
Within this cohort, topical ruxolitinib was administered to 27 patients following its recent approval, showing signals of improved control when prior topical tacrolimus therapy proved inadequate. Furthermore, a small subgroup of eight patients receiving a combination of topical ruxolitinib and topical corticosteroids on top of tacrolimus saw BSA reductions climb from 51.0% at 12 months to 74.0% at 24 months.
Targeted Interventions for Body Involvement
Treatment responses on the body differ from those observed on the head and neck. According to the registry findings presented in Minneapolis, adding topical corticosteroids to topical tacrolimus for body involvement yielded measurable BSA reductions at 6 months (47.3% versus 25.0%) and 12 months (50.0% versus 29.2%). Incorporating an excimer laser alongside tacrolimus produced further gains, driving reductions to 56.7% at 6 months and 66.7% at 12 months compared with 25.0% and 29.2% for tacrolimus alone.
Thyroid Screening Recommended in Pediatric Workup
The registry data also evaluate the relationship between pediatric vitiligo and thyroid disease. Because thyroid disease functions as a potentially modifiable risk factor, Silverberg stated that thyroid screening should be integrated into routine clinical workups. Relying exclusively on thyroid-stimulating hormone (TSH) tests risks missing half of the kids who have a risk factor for severe disease.
Managing Patient and Family Expectations
Because repigmentation is a slow and cumulative process, clinicians emphasize the importance of setting realistic expectations for families. According to Silverberg, visible changes on the head and neck may take 3 months or more to appear, with maximum therapeutic responses extending out to 36 months. Lawrence F. Eichenfield, chief of pediatric and adolescent dermatology at Rady Children’s Hospital and professor of dermatology and pediatrics at the University of California, San Diego, noted that these real-world registry insights can be part of the effort to better understand how to prioritize therapeutic strategies.
Related reading